Br J Urol 1998 Dec;82(6):829-34
Department of Urology, University of Athens, School of Medicine, Sismanoglio Hospital, Greece.
Urol Int 2004 ;72(4):284-91
Department of Urology, Agios Andreas Regional Hospital of Patras, Patras, Greece.
Objective: To determine the efficacy and safety of two different doses of intravesical mitoxantrone and of recombinant interferon-alpha (IFNalpha-2b), instilled after transurethral resection (TUR) of superficial transitional cell carcinoma (TCC) of the bladder.
Material And Methods: 208 patients (mean age 62.05 years) with primary or recurrent superficial (TaG1, T1G1, T1G2) bladder cancer were randomly allocated into four groups, after TUR of all visible tumors. Read More
Br J Urol 1995 Dec;76(6):697-701
Seinäjoki Central Hospital, Finland.
Objectives: To evaluate the efficacy of intravesical epirubicin with or without alpha 2b-interferon (alpha 2b-IFN) as a prophylactic treatment for recurrent superficial transitional cell carcinoma (TCC) of the urinary bladder.
Patients And Methods: A total of 81 patients with superficial (stage Ta and T1), well or moderately differentiated (grades 1 and 2) TCC were treated between June 1988 and December 1993. The patients were randomized into three groups: Group 1 was treated by transurethral resection (TUR) alone; Group 2 received 50 mg epirubicin and Group 3 received 50 mg epirubicin combined with 10 MU alpha 2b-IFN, intravesically in 50 mL sterile buffer solution. Read More
Arch Esp Urol 1995 Jun;48(5):479-88
Servicio de Urologia, Hospital Universitario, Marqués de Valdecilla, Santander, España.
Objective: To assess the efficacy of 60 MU intravesical alpha-2b interferon (IFN) in preventing recurrence of transitional cell carcinoma of the bladder.
Methods: A prospective, randomized double-blind study was conducted to assess the efficacy of 60 MU intravesical alpha-2b IFN compared to a control group. T1G2-G3 and the G1 recurrent tumors were included in the study (30 in each group). Read More
Bratisl Lek Listy 2000 ;101(6):317-20
Department of Urology and Andrology, University Hospital, Bratislava, Slovakia.
Objective: To ascertain the effect of intravesical instillation of Alpha 2-b Interferon (IFN a-2) 10 million I.U. in 50 ml physiological saline as a monotherapy and in combination with Farmarubicin (FRC) 50 mg dissolved together in 50 ml of physiological saline. Read More